Search research articles
Contact Us
Filters
Showing results (41-50 of 91) with videos related to
Page
of 10
Sort By:
Anti-Cancer Drugs
|
March 6, 2021
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib
Roberta Minari, Alessandro Leonetti, Letizia Gnetti, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 15, 2025
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
International Journal of Molecular Sciences
|
July 26, 2020
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
Mara Bonelli, Rita Terenziani, Silvia Zoppi, et al.
Frontiers in Oncology
|
October 19, 2020
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Biomedicines
|
September 28, 2023
Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention?
Giovanni Cimmino, Francesco Natale, Roberta Alfieri, et al.
Clinical and Experimental Medicine
|
April 10, 2025
Isolation and characterization of extracellular vesicles from EGFR mutated lung cancer cells
Dian Jamel Salih, Katrin S Reiners, Roberta Alfieri, et al.
Targeted Oncology
|
September 11, 2019
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
Silvia La Monica, Roberta Minari, Daniele Cretella, et al.
Cancers
|
July 24, 2021
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
Maicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, et al.
Translational Oncology
|
October 6, 2018
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Karim Rihawi, Roberta Alfieri, Michelangelo Fiorentino, et al.
Current Cancer Drug Targets
|
February 1, 2023
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice
Silvia La Monica, Valentina Coccé, Mara Bonelli, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 91) with videos related to
Sort By:
Page
of 10
Anti-Cancer Drugs
|
March 6, 2021
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib
Roberta Minari, Alessandro Leonetti, Letizia Gnetti, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 15, 2025
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
International Journal of Molecular Sciences
|
July 26, 2020
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
Mara Bonelli, Rita Terenziani, Silvia Zoppi, et al.
Frontiers in Oncology
|
October 19, 2020
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Biomedicines
|
September 28, 2023
Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention?
Giovanni Cimmino, Francesco Natale, Roberta Alfieri, et al.
Clinical and Experimental Medicine
|
April 10, 2025
Isolation and characterization of extracellular vesicles from EGFR mutated lung cancer cells
Dian Jamel Salih, Katrin S Reiners, Roberta Alfieri, et al.
Targeted Oncology
|
September 11, 2019
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
Silvia La Monica, Roberta Minari, Daniele Cretella, et al.
Cancers
|
July 24, 2021
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
Maicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, et al.
Translational Oncology
|
October 6, 2018
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Karim Rihawi, Roberta Alfieri, Michelangelo Fiorentino, et al.
Current Cancer Drug Targets
|
February 1, 2023
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice
Silvia La Monica, Valentina Coccé, Mara Bonelli, et al.
Page
of 10